Investigating the repurposing potential of immune checkpoint inhibition for cancer treatment using Mendelian randomisation.

Bate T, Dong M, Liu Y, Seviiri M, Brown MC, Atkins J, Smith-Byrne K, Practical Consortium, Hung R, Law M, Iles M, Ghajari H, Lo S, Gusev A, Vanderwerff B, Zoellner S, Liu G, Xu W, Martin R, Yarmolinsky J, Haycock P

Open source

DOI
10.21203/rs.3.rs-9656350/v1
Published
2026 Jul 28
Container
Research square
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.21203/rs.3.rs-9656350/v1,
  title = {Investigating the repurposing potential of immune checkpoint inhibition for cancer treatment using Mendelian randomisation.},
  author = {Bate T and Dong M and Liu Y and Seviiri M and Brown MC and Atkins J and Smith-Byrne K and Practical Consortium and Hung R and Law M and Iles M and Ghajari H and Lo S and Gusev A and Vanderwerff B and Zoellner S and Liu G and Xu W and Martin R and Yarmolinsky J and Haycock P},
  year = {2026},
  journal = {Research square},
  doi = {10.21203/rs.3.rs-9656350/v1},
  url = {https://doi.org/10.21203/rs.3.rs-9656350/v1}
}

RIS

TY  - JOUR
TI  - Investigating the repurposing potential of immune checkpoint inhibition for cancer treatment using Mendelian randomisation.
AU  - Bate T
AU  - Dong M
AU  - Liu Y
AU  - Seviiri M
AU  - Brown MC
AU  - Atkins J
AU  - Smith-Byrne K
AU  - Practical Consortium
AU  - Hung R
AU  - Law M
AU  - Iles M
AU  - Ghajari H
AU  - Lo S
AU  - Gusev A
AU  - Vanderwerff B
AU  - Zoellner S
AU  - Liu G
AU  - Xu W
AU  - Martin R
AU  - Yarmolinsky J
AU  - Haycock P
PY  - 2026
JO  - Research square
DO  - 10.21203/rs.3.rs-9656350/v1
UR  - https://doi.org/10.21203/rs.3.rs-9656350/v1
ER  - 

APA

T, B., M, D., Y, L., M, S., MC, B., J, A., K, S., Consortium, P., R, H., M, L., M, I., H, G., S, L., A, G., B, V., S, Z., G, L., W, X., R, M., J, Y., & P, H. (2026). Investigating the repurposing potential of immune checkpoint inhibition for cancer treatment using Mendelian randomisation.. Research square. https://doi.org/10.21203/rs.3.rs-9656350/v1

Source records